Carrera F, Silva J G, Oliveira C, Frazao J M, Pires C
Renal Unit, National Medical Center, Lisbon, Portugal.
Nephron. 1994;68(1):38-40. doi: 10.1159/000188084.
In order to evaluate the persistence of antibodies against hepatitis C virus (HCV) in a chronic hemodialysis population, we studied 151 HBsAg-negative patients. Anti-HCV titers were evaluated every 3 months over 1 year, and the serum alanine aminotransferase/serum aspartate aminotransferase ratio monthly from the start of hemodialysis. The anti-HCV titers (ELISA C100-3) remained stable in 127 patients and fluctuated in 24, without an evident correlation with hepatic function. Using our criteria, we found 85 patients with non-A, non-B hepatitis, 57 of them with biochemical criteria of chronic hepatic disease. There was a strong correlation between antibodies to HCV and non-A, non-B hepatitis (chi 2; p < 0.05) which was more marked in those patients with biochemical criteria of chronic hepatic disease (chi 2; p < 0.001). We concluded that the anti-HCV titer is reliable as a long-term marker of hepatitis C virus infection.
为了评估慢性血液透析人群中抗丙型肝炎病毒（HCV）抗体的持久性，我们研究了151例HBsAg阴性患者。在1年的时间里，每3个月评估一次抗HCV滴度，从血液透析开始每月评估血清丙氨酸氨基转移酶/血清天冬氨酸氨基转移酶比值。127例患者的抗HCV滴度（ELISA C100-3）保持稳定，24例患者的抗HCV滴度波动，与肝功能无明显相关性。根据我们的标准，我们发现85例非甲非乙型肝炎患者，其中57例有慢性肝病的生化标准。抗HCV抗体与非甲非乙型肝炎之间存在很强的相关性（卡方检验；p<0.05），在有慢性肝病生化标准的患者中这种相关性更明显（卡方检验；p<0.001）。我们得出结论，抗HCV滴度作为丙型肝炎病毒感染的长期标志物是可靠的。
